Form SC 13D Therapeutics Acquisition Filed by: RA CAPITAL MANAGEMENT, L.P. Jun 30, 2021 04:33PM
POINT Biopharma Debuts as Publicly Traded Next-Generation Radiotherapeutics Company Jun 30, 2021 04:05PM
POINT Biopharma Debuts as Publicly Traded Next-Generation Radiotherapeutics Company Jun 30, 2021 04:05PM
Form 3 Therapeutics Acquisition For: Jun 23 Filed by: RA CAPITAL MANAGEMENT, L.P. Jun 24, 2021 07:03PM
Research Alliance Corp. I Announces Effectiveness of Registration Statement for Proposed Business Combination with POINT Jun 9, 2021 04:30PM


Jun 4, 2021 08:32AM POINT Biopharma Doses First Patients in Phase 3 Study of PNT2002 for mCRPC (RACA)
Jun 4, 2021 08:30AM POINT Biopharma Announces First Patients Dosed in Phase 3 Study of PNT2002 for mCRPC
Jun 4, 2021 06:30AM POINT Biopharma Announces First Patients Dosed in Phase 3 Study of PNT2002 for mCRPC
Jun 4, 2021 06:30AM POINT Biopharma Announces First Patients Dosed in Phase 3 Study of PNT2002 for mCRPC
Jun 1, 2021 04:33PM POINT Biopharma Receives U.S. Nuclear Regulatory Commission Materials License for Indiana Facility (RACA)
Jun 1, 2021 04:31PM POINT Biopharma Receives U.S. Nuclear Regulatory Commission Materials License for Indiana Facility
Apr 28, 2021 09:07AM POINT Biopharma Receives U.S. Nuclear Regulatory Commission Materials License for Indiana Facility
Mar 15, 2021 06:35AM POINT Biopharma to list on NASDAQ through merger with Research Alliance Corp. I (RACA)
Mar 15, 2021 06:00AM Next-generation Radiopharmaceuticals Company POINT Biopharma to list on NASDAQ through merger with Research Alliance Corp. I
Mar 15, 2021 06:00AM Next-generation Radiopharmaceuticals Company POINT Biopharma to list on NASDAQ through merger with Research Alliance Corp. I